What's Next For Cell And Gene Therapies In 2023 And Beyond

Despite some challenging, up-and-down years, the cell and gene therapy sector has flourished due to continued investor confidence. Specifically, in 2022, therapeutic advances were reported to generate “a lot of hope for patients.” However, the current downturn in the economy has negatively affected that confidence, raising questions about the sector’s prospects for 2023 and beyond.

In October 2022, a panel discussion at the Cell & Gene Meeting on the Mesa, sponsored by Precision ADVANCE, featured the following industry leaders:

• Stewart Abbot, Chief Scientific Officer, Turnstone Biologics
• Laura Lande-Diner, Chief Business Officer, Satellite Bio
• Robert Peters, Chief Scientific Officer, Ensoma

Moderated by Anshul Mangal, President of Project Farma and Precision ADVANCE, gain insight from the collective's take on where the industry is headed.